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Abstract
Background: Study pain and use of pain medications and their predictors after primary Total Hip Arthroplasty (THA).
Methods: We examined whether gender, age (reference, < = 60 yrs), body mass index (BMI; reference, <25 kg/m2)), 
comorbidity measured by Deyo-Charlson index (5-point increase), anxiety and depression predict moderate-severe hip 
pain and use of pain medications 2- and 5-years after primary THA. Multivariable logistic regression adjusted for these 
predictors and distance from medical center, operative diagnosis, American Society of Anesthesiologists (ASA) score 
and implant type.
Results: Moderate-severe pain was reported by 8.1% at 2-years and 10.8% at 5-years. Significant predictors of 
moderate-severe pain at 2-year follow-up were [Odds ratio (95% confidence interval)]: BMI 35-39.9, 1.8 (1.2,2.8); BMI > = 
40, 1.7 (1.0,2.9); depression, 2.1 (1.4,3.0). Moderate-severe pain at 5-years was more common in patients with higher 
BMI: 25-29.9, 1.5 (1.1,2.1); 30-34.9, 1.8 (1.2,2.6); 35-39.9, 1.9 (1.2,3.1); and > = 40, 3.1 (1.7,5.7).
Significant predictors of NSAID use were [Odds ratio (95% confidence interval)]: female gender at 2- and 5-years, 1.4
(1.1,1.7) and 1.4 (1.1,1.8); BMI 35-39.9 at 2-years, 1.9 (1.4, 2.6) and 30-34.9 at 2-years, 1.7 (1.2,2.4); and depression at 5-
years, 1.8 (1.2,2.8).
Significant predictors of opioid medication use were [Odds ratio (95% confidence interval)]: female gender at 2- and 5-
years, 2.0 (1.1,3.0) and 2.4 (1.4,4.0); BMI 30-34.9 at 2-years, 2.0 (1.0,3.9); and depression at 2-years, 2.0 (1.1,3.7).
Conclusions: Higher BMI and depression impacted moderate-severe pain; and female gender, higher BMI and 
depression predicted use of pain medications at 2- and 5-years post-primary THA.
Background
Primary Total Hip Arthroplasty (THA) is an extremely
successful surgery [1] associated with significant pain
relief and improvement in function and quality of life [2].
Implant survival studies indicate a very low failure rate of
<1% per year [3,4]. While important clinical outcomes/
complications such as fracture, infection and revision
have been studied well, well-designed studies assessing
patient-reported outcomes have been getting more atten-
tion in the last decade [5]. Pain is the number one reason
for patients undergoing these procedures and therefore
recurrence and/or persistence of significant hip pain after
THA is of great concern for both patients and surgeons.
While several important unmodifiable patient character-
istics such as age and gender can impact pain outcomes
following primary THA, it is important to know whether
modifiable factors such as Body Mass Index and comor-
bidity impact pain following primary THA.
Are Body mass index (BMI) and comorbidity associated
with pain outcomes after THA? The evidence is contra-
dictory. BMI was associated with more pain at 6-12
months post-primary THA in one study [6], but not in
others [7-9]. Comorbidity was found to be associated
with pain outcomes post-THA in all studies [7,9-11]
except one [6]. The main limitation of most previous
studies is a small sample size that makes them underpow-
ered to detect significant associations, thereby leading to
false negative results. These studies also differed in mea-
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sures of pain outcomes, length of follow-up and con-
founders adjusted in the analyses.
Non-modifiable factors of interest, such as gender have
also been studied. Some studies have reported that female
gender is associated with worse pain outcomes post-pri-
mary THA [7,9,12], while other studies found no gender
association [10,11,13,14]. Similarly, younger age was
associated with more pain 1-15 years post-THA [9,12-
14], while others found no difference in pain outcomes by
age, at 6-12 months [6,7,10,11,15]. A recent systematic
review assessing prognostic factors for patient outcomes
in THA studies up to 2001 reported that female gender
was associated with less post-operative pain, after THA
[16].
We hypothesized that at 2- and 5-years post-THA: (1)
higher body mass index and comorbidity will be associ-
ated with worse pain outcomes; (2) pre-operative depres-
sion and anxiety, female gender and younger age will be
associated with worse pain outcomes and higher use of
pain medications.
Methods
We used the data collected prospectively in the Mayo
Total Joint Registry, detailed in previous studies [17,18].
Starting in 1993, all patients who underwent hip arthro-
plasty at the Mayo Clinic received a hip questionnaire
that included questions regarding hip pain and function
[19]. This validated questionnaire was administered at 2-
and 5-years post-operatively by mail or in person at the
clinical follow-up visit [20,21]. Patients who did not
return the mailed survey and failed to return for follow-
up clinic visits, had the questionnaire administered on
the telephone by experienced registry staff. The study
was approved by the Mayo Clinic Institutional Review
Board. Several studies using these questionnaires and
outcomes in knee and hip arthroplasty patients have been
published or are in press [22-25]. The study cohort con-
sisted of all patients who underwent primary THA at the
Mayo Clinic, Rochester between 1993 and 2005 and were
alive at the 2- or 5-year follow-up. We did not restrict by
age group or diagnosis. A total of 9,154 THAs at 2- and
6,243 THAs at 5-year were eligible for the study.
Outcomes of Interest
We assessed the prevalence of moderate-severe pain and
the use of pain medications for THA pain at both 2- and
5-years post-primary THA. The pain question was: "How
much pain do you have in your operated hip?" patients
could respond- 'none', 'mild', 'moderate', 'severe'; none/
mild was reference and moderate and severe categories
were combined. A combined outcome of moderate-
severe pain was chosen for several reasons: (1) the pri-
mary reason for undergoing THA is moderate-severe hip
pain; and according to the clinical opinion of the senior
orthropedic surgeon (D.L.) this was an undesirable out-
come following THA, a major elective surgery; (2) this
outcome was chosen a priori, before performing any data
analyses except examining the prevalence of severe and
moderate pain; and (3) even with a long follow-up dura-
tion of 13 years, very small number of patients had severe
pain, making the multivariable analyses not meaningful.
Use of pain medications was assessed separately for
NSAIDs and opioid medications. Patients were asked the
following question "Do you use any of the following med-
ications for the pain in your operated hip?" Patients could
choose one or more responses from - 'none', 'Non-steroi-
dal anti-inflammatory drugs (NSAIDs)', 'narcotics' or
'oral steroids'. We used none/oral steroid as the reference
category and use of opioids and NSAIDs separately. This
was based on the a priori determination by the senior
orthopedic surgeon that the risks and implications of
NSAIDs use are much different from the use of the opioid
medications. Thus, clinically these outcomes are distinct.
Oral steroids are used for reducing joint and/or systemic
inflammation, usually but not always associated with sig-
nificant pain and some patients may be chronically ste-
roid-dependent. Additionally, only a small fraction of
patients reported oral steroid use, making it impossible to
analyze as a separate outcome.
Predictors of Interest
The predictors of interest were categorized as: (1)
unmodifiable - age and gender; and (2) modifiable - BMI,
comorbidity, depression and anxiety. Age was catego-
rized, as previously [22,26] into ≤ 60, 61-70, 71-80 and
>80. BMI was categorized, as previously [27] into ≤ 25,
25.1-29.9, 30-34.9, 35-39.9 and ≥ 40. Comorbidity mea-
sured by Deyo-Charlson score, a validated comorbidity
measure [28] was treated as a continuous variable, and we
assessed the association of 5-point increase with out-
comes. This is the most commonly used comorbidity
measure consisting of a weighted scale of 17 comorbidi-
ties (including cardiac, pulmonary, renal, hepatic disease,
diabetes, cancer, HIV etc.), expressed as a summative
score [29,30]. Depression and anxiety were assessed by
the presence or absence of International Classification of
Diseases- ninth revision (ICD)-9 codes before the THA.
Statistical Analyses
Baseline clinical and demographic characteristics of
patients were compared using Student's t-test for contin-
uous and chi-square tests for categorical measures.
Responder and non-responder characteristics were com-
pared using logistic regression analyses.
Univariate and multivariable-adjusted logistic regres-
sion analyses were performed for each outcome at 2- and
5-years. For these analyses, we used a Generalized Esti-
mating Equations (GEE) approach to adjust for the corre-Singh and Lewallen BMC Musculoskeletal Disorders 2010, 11:90
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lation between observations on the same subject due to
replacement of both hips. In addition to adjusting for pri-
mary predictors of interest -age, gender, BMI, comorbid-
ity, anxiety and depression, all logistic regression analyses
were also adjusted for the following potential confound-
ers: (1) operative diagnosis- osteoarthritis, rheumatoid/
inflammatory arthritis, avascular nerosis and other; (2)
distance from the medical center- <100, 100-500 and
>500 miles/overseas; (3) implant type- cemented, unce-
mented, hybrid; and (4) ASA class: Class I or II vs. III/IV.
Distance from the medical center was included, since
Mayo Clinic provides THA as a primary medical center
for the local residents, but is also referral center for
patients traveling from far, who may have different sever-
ity of disease and different level of expectation; both can
impact pain outcomes [31]. We present only the multi-
variable-adjusted estimates for the ease of understanding.
Odds ratios and the 95% confidence intervals are pre-
sented. The odds ratio defines the risk of an outcome in
those with the risk factor compared to those without,
such that a number >1 indicates higher occurrence of the
outcome in those with each specific risk factor. A p-value
< 0.05 and 95% confidence interval excluding one indi-
cates statistical significance.
Each author certifies that his or her institution has
approved the human protocol for this investigation and
that all investigations were conducted in conformity with
ethical principles of research.
Results
Characteristics of the study population and the non-
responders
The characteristics of responders at 2- and 5-years were
similar, as described in Table 1. The survey response rate
was 62.3% (5,707/9,154) at 2- and 52.7% (3,289/6,243) at
5-years post-primary THA. In this study, we studied
5,707 primary THAs at 2-years and 3,289 primary THAs
at 5-years. At 2-years post-primary THA, the mean age of
responders was 65 years, 51% were female, 30% were ≤60
years, 24% had BMI <25 kg/m2, 35% had an uncemented
implant and the underlying diagnosis was osteoarthritis
in 87% (Table 1). The response rate was 62.3% (5,707/
9,154) at 2-years and 52.7% (3,289/6,243) at 5-years post-
primary THA. 95% of patients each from 2-year and 5-
year follow-up cohorts reported moderate-severe pain in
the index hip at pre-surgery evaluation.
Survey responders at 2-years post-primary THA were
more likely to be older (age 61-70, 71-80 and >80 with
odds ratios (OR), 1.4, 1.3 and 1.3, compared to ≤ 60 years)
and less likely to have BMI ≥ 40 (OR, 0.7), ASA class III-
IV (OR, 0.9) or live farther from the medical center (dis-
tance >100-500 and >500 miles with OR 0.9 and 0.7). At
5-years, responders were more likely to be older (age 61-
70, 71-80 with OR, 1.4 and 1.4), BMI 25-29.9 (OR, 1.2),
and less likely to live farther from the medical center (dis-
tance >100-500 and >500 miles with OR 0.9 and 0.6).
Prevalence of pain and use of pain medications after THA
Moderate-severe pain was reported by 8.1% (435/5,390)
at 2-years and 10.8% (339/3,130) at 5-years. NSAID use
was reported by 12% (607/5,064) at 2- years and 12.7%
(382/3,005) at 5-years. Opioid medication use was
reported by 2.3% (118/5,064) at 2- years and 2.8% (85/
3,005) at 5-years.
Predictors of Moderate-severe pain after Primary THA
Two years after primary THA, we noted significantly
higher odds of moderate-severe hip pain in patients with
BMI 35-39.9 and ≥ 40 with odds of 1.8 and 1.7, compared
to BMI <25; and presence of depression increased the
odds of moderate-severe pain to 2.1, compared to those
without depression (Table 2). Gender, age, comorbidity
and presence of anxiety were not significantly associated
with hip pain.
At 5-years post-primary THA, all BMI categories above
25 were significantly associated with higher odds of mod-
erate-severe hip pain, with increasing odds with increas-
ing BMI (Table 2). Gender, age, comorbidity, anxiety and
depression were not significantly associated.
Predictors of Use of NSAID and Opioid Pain medications 
after Primary THA
NSAID use
At 2-years, NSAID use was significantly higher in women
with odds of 1.4, in patients with BMI of 35-39.9 with
odds of 1.9 and in patients with depression with odds of
2.0 (Table 3). At 5-years, women had 1.4 times odds of
NSAID use and those with BMI 30-34.9 kg/m2, 1.7 times.
Opioid medication use
Two years after primary THA, women had odds of 2.0,
and those with depression odds of 2.0, of using opioid
medications (Table 4). Five years after primary THA, opi-
oid medication use was significantly higher in women
with odds of 2.4 and in patients with BMI 30-34.9 kg/m2
with odds of 2.0.
Discussion and conclusions
In this study, we found that higher body mass index was
a s s o c i a t e d  w i t h  s i g n i f i c a n t l y  h i g h e r  o d d s  o f  m o d e r a t e -
severe hip pain and use of NSAID medications 2-years
after primary THA. At 2-years post-primary THA,
female gender was associated with higher odds of NSAID
and opioid medication use. Depression was associated
with higher odds of moderate-severe pain and opioid
medica tion use a t 2-years post -primary THA. Most of
these associations were still significant at 5-years.
Our study has many novel findings that merit further
discussion. We believe our study is among the first toSingh and Lewallen BMC Musculoskeletal Disorders 2010, 11:90
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provide the estimates of NSAIDs and opioid medication
use after primary THA in a large sample of patients.
Despite several studies of pain after THA, quite surpris-
ingly, the prevalence of pain medication use at intermedi-
ate- or long-term follow-up after THA has not been
described. In this large sample of patients, we provide
estimates of moderate-severe pain at intermediate-term
follow-up after primary THA. This information can be
provided at pre-operative counseling so that patients
have realistic expectations from the procedure. Studies
are needed to examine use of these mediations at long-
term follow-up after THA.
Second, depression predicted moderate-severe pain
and higher opioid medication use 2-years post-primary
THA. Previous studies in primary knee arthroplasty
patients have reported that depression predicts pain at 1-
[32], 2- [33] and 5-years [34]. To our knowledge, there are
no published studies that have examined whether depres-
sion is associated with pain or pain medication use after
primary THA. Our findings suggest that screening for
depression prior to surgery may help identify patients at-
risk for poorer pain outcomes and opioid use 2-years
after THA. A potential explanation of association of
baseline depression with 2-year outcomes may be higher
pain perception and reporting by those with depression
Table 1: Characteristics of patients
Primary THA
2-year (n = 5,707) 5-year (n = 3,289)
Mean Age (± SD) 65.0 ± 13.3 64.7 ± 12.9
Men/Women (%) 49%/51% 47%/53%
Age groups n (%)
≤ 60 yrs 30% 30%
>60-70 yrs 31% 32%
>70-80 yrs 30% 31%
>80 yrs 9% 6%
Body Mass index (in kg/m2)




≥ 40 4% 4%
Missing 1% 1%
ASA Score
Class I-II 62% 64%











Avascular Necrosis 7% 8%
Othera 4% 4%
aOther category includes congenital dislocated hip, neoplasm, fracture, Legg-Calvé-Perthe's etc.Singh and Lewallen BMC Musculoskeletal Disorders 2010, 11:90
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than those without depression. Further studies need to
examine if treatment of depression in the pre- or post-
operative period improves pain outcomes and opioid
medication use 2-years after THA. At 5-years, these asso-
ciations were not significant. The lack of significance
with 5-year outcomes may be due to smaller sample size
at 5-years compared to 2-years, longer duration since
depression diagnosis or simple lack of any association at
5-years.
The third important finding in this study is that higher
BMI significantly predicted a higher risk of moderate-
severe hip pain at 2- and 5-years. This finding confirms a
similar finding in one other study of 193 patients at 6-12
months post-primary THA [6], but is in contrast to three
multivariable-adjusted studies that found no such associ-
ation at 0.5-years [7] or at 15-years [8,9]. All previous
studies were multivariable-adjusted, similar to our study.
Previous studies had examined BMI as a continuous [6,7]
or three-level categorical variable (<25, 25-30, >30) [8,9],
compared to 5-level categorical variable in our study, as
per the WHO classification [27]. The main reason for two
of the previous studies being negative was small sample
size, making them liable to type II error, i.e., missing an
effect when one exists due to a small sample size. We cat-
egorized BMI as per WHO classification [27], since our
sample size was large enough to not restrict us to fewer
categories. Another interesting observation was a dose-
relationship of increasing BMI with moderate-severe pain
at 5-year follow-up.
Fourth, the association of female gender with NSAID
use and opioid medication use at 2- and 5-years, but not
moderate-severe pain merits some discussion. Lack of
gender-pain associations in our study is similar to many
studies [10,11,13,14], but in contrast to others [7,9,12].
Higher odds of use of NSAIDs and opioid medications in
women versus men with primary THA is similar to
higher analgesic use reported for women in national
cohorts of patients in US and Sweden [35,36]; our study
extends this finding to THA cohorts. Our finding of lack
of gender and pain severity in THA patients is also inter-
esting, since we have reported higher prevalence of pain
in women at 2- and 5-year post-TKA from the same data-
set [22]. Thus, gender has different impact on pain out-
comes after THA versus TKA.
Lastly, the lack of association of older age with pain
outcomes confirmed similar findings in studies of pri-
mary THA [6,7,10,11], in contrast to others [9,12-14].
Again, it is interesting that age associations we noted in
post-TKA outcomes from the same dataset were not true
for post-THA [22].
Table 2: Multivariable* Predictors of Moderate-severe Pain
Multivariable-adjusted 2-year Multivariable-adjusted 5-year
Odds Ratio (95% 
Confidence 
Interval)






1.1 (0.9, 1.4) 0.30 1.2 (0.9, 1.5) 0.18
Age (Ref, ≤ 60 yrs)
>60-70 yrs 0.7 (0.6, 1.0) 0.06 0.8 (0.6, 1.1) 0.17
>70-80 yrs 1.1 (0.8, 1.6) 0.45 0.8 (0.6, 1.2) 0.32
>80 yrs 1.5 (1.0, 2.3) 0.07 0.6 (0.3, 1.1) 0.11
BMI (Ref, <25 kg/m2)
25-29.9 1.0 (0.7, 1.3) 1.00 1.5 (1.1, 2.1) 0.02
30-34.9 1.3 (1.0, 1.8) 0.07 1.8 (1.2, 2.6) <0.01
35-39.9 1.8 (1.2, 2.6) <0.01 1.9 (1.2, 3.1) 0.01




1.0 (0.8, 1.3) 0.98 0.9 (0.7, 1.3) 0.75
Anxiety (Ref, no) 0.9 (0.5, 1.4) 0.58 1.1 (0.6, 2.1) 0.76
Depression (Ref, no) 2.1 (1.4, 3.0) <0.01 1.3 (0.8, 2.2) 0.30
*Adjusted for ASA score, distance from the medical center, income and the operative diagnosis, in addition to the above variables
Regression: n/N = 409/5,154 at 2-yr FU; n/N = 318/2,929 at 5-yr FU; Numbers in Bold indicate significant Odds ratios and p-valuesSingh and Lewallen BMC Musculoskeletal Disorders 2010, 11:90
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Our study has several strengths. We examined the
NSAID and opioid medication use alongside pain assess-
ment at both 2- and 5-years after primary THA in a large
cohort. This is the most important contribution of this
study. Most previous studies were limited to 1-2 year fol-
low-up and had not included study of use of pain medica-
tions for residual pain after THA. The study of use of pain
medications is an important outcome, which is under-
studied in the arthroplasty literature. We controlled for
several important confounders and covariates and our
estimates of association were robust i.e., changed very lit-
tle between univariate and multivariable models.
Our study has several limitations. Non-response and
referral bias may limit generalizability to general popula-
tions. The response rate of 62% at 2-years and 53% at 5-
years, is similar to the average response rate of 60% in
large surveys of this size [37]. A higher response rate is
always more desirable. The estimates of association in
this study are conservative, since non-responders were
more likely to be younger, have ASA class III-IV and live
>100 miles away from the medical center and the same
ca t eg ories  t ha t  a lso r eport ed mo r e  pa in.  Res idual  c on-
founding is possible in this cohort study due to our inabil-
ity to control for pre-operative pain in the main analyses,
since this would have led to selection bias with only less
t h a n  h a l f  s u b j e c t s  e l i g i b l e  i n  e a c h  c a t e g o r y .  W e  w e r e
unable to adjust for acute pain management after THA,
which may impact chronic postoperative pain [38].
Depression and anxiety would be best captured by exami-
nation by a psychologist or use of validated instruments
such as Center for Epidemiological Studies Depression
(CES-D) scale or Beck's Depression Inventory. This was a
retrospective analysis of prospectively collected data of
all-comers for THA over a 12-year period that did not
include depression questionnaires; and psychiatric evalu-
ation of every patient undergoing THA is neither feasible
nor clinically appropriate. Currently there is no National
U.S. Joint Registry, and therefore an analysis of data col-
lected over a considerable time-period from a large vol-
ume medical center (such as this) is the next best
approach. Future studies can examine the predictors of
moderate and severe categories separately, if it is clini-
cally indicated.
In summary, we studied pain severity and use of pain
medications 2- and 5-years after primary THA in a large
cohort of patients. We noted significant impact of BMI
on moderate-severe pain and use of pain medications 2-
and 5-years after THA. Associations with depression
with moderate-severe pain were significant at 2-years,
but not at 5-year follow-up. Female gender was associ-
ated with more pain medication use, but similar pain out-
come. This study identifies modifiable factors for pain
Table 3: Multivariable* Predictors of Use of NSAID medications
Multivariable-adjusted 2-year Multivariable-adjusted 5-year
Odds Ratio (95% 
Confidence 
Interval)






1.4 (1.1, 1.7) <0.01 1.4 (1.1, 1.8) <0.01
Age (Ref, ≤ 60 yrs)
>60-70 yrs 1.1 (0.9, 1.4) 0.34 0.9 (0.7, 1.3) 0.70
>70-80 yrs 1.3 (0.9, 1.7) 0.12 0.9 (0.6, 1.3) 0.49
>80 yrs 1.4 (0.9, 2.0) 0.12 1.1 (0.6, 1.9) 0.79
BMI (Ref, <25 kg/m2)
25-29.9 1.0 (0.8, 1.3) 0.99 1.4 (1.0, 1.8) 0.06
30-34.9 1.2 (0.9, 1.5) 0.28 1.7 (1.2, 2.4) <0.01
35-39.9 1.9 (1.4, 2.6) <0.01 1.5 (1.0, 2.4) 0.07
≥ 40 1.6 (1.0, 2.5) 0.04 1.9 (1.1, 3.4) 0.03
Deyo-Charlson index 
(5-point change)
1.0 (0.7, 1.3) 0.81 1.1 (0.8, 1.5) 0.58
Anxiety (Ref, no) 1.2 (0.8, 1.8) 0.46 0.8 (0.5, 1.5) 0.56
Depression (Ref, no) 1.1 (0.8, 1.6) 0.52 1.8 (1.2, 2.8) <0.01
*Adjusted for ASA score, distance from the medical center, income and the operative diagnosis, in addition to the above variables
Regression: n/N = 575/4,830 at 2-yr FU; n/N = 362/2,807 at 5-yr FU; Numbers in Bold indicate significant Odds ratios and p-valuesSingh and Lewallen BMC Musculoskeletal Disorders 2010, 11:90
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outcomes, which can be targeted with pre- or post-opera-
tive interventions in future studies.
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